MaryDickinsonChamberlinMD

Oncology • Lebanon, NH

Associate Professor, Medicine, Geisel School of Medicine

Join to view full profile

Dr. Chamberlin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chamberlin's full profile

Already have an account?

Office
1 Medical Center Dr
Dartmouth-Hitchcock Medical Center - Nccc
Lebanon, NH 03756
Phone+1 603-653-6181

Education & Training

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 2004 - 2006
University of Vermont Medical CenterResidency, Internal Medicine, 2000 - 2003
University of Vermont College of MedicineClass of 2000

Certifications & Licensure

VT State Medical License 2000 - 2026
NH State Medical License 2003 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
ACTIVE_NOT_RECRUITING
PHASE3
Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy Start of enrollment: 2011 Feb 01
Unknown status
Not Applicable
Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway Start of enrollment: 2012 Dec 01
Terminated
Not Applicable
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer Start of enrollment: 2013 Dec 01
Terminated
Genetically-informed Therapies for Patients With Metastatic Cancer Start of enrollment: 2014 Jan 01
Withdrawn
Phase 4
A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer Start of enrollment: 2014 Jun 01
Completed
Not Applicable
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) Start of enrollment: 2016 Feb 25
Withdrawn
Phase 2
Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) Start of enrollment: 2021 Aug 13
RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer.
Steven Tau, Mary D Chamberlin, Huijuan Yang, Jonathan D Marotti, Patricia C Muskus
Cancer Research. 2025-03-14
Resolution of Pyoderma Gangrenosum During Adjuvant Breast Cancer Therapy.
Abigail P Lauder, Anita Nwiloh, Matthew Eximond, Robert E LeBlanc, Alicia T Dagrosa
Journal of Clinical Medicine. 2025-02-17
Prevalence of Human Papillomavirus-Associated Head and Neck Cancer in Rwanda: A 10-Year Review.
Fidel Rubagumya, Lydia Businge, Wilma H Hopman, Gad Murenzi, Aline Uwimbabazi
Cancer Medicine. 2024-11-01

Press Mentions

Virginia Department of Health to Open Community Vaccination Center in Fredericksburg for Booster ShotsOctober 14th, 2021
COVID Hospitalizations Double in Stafford County in 5 DaysAugust 3rd, 2021
Northern Virginia Counties Promote Vaccines as Rates StallJuly 26th, 2021
Join now to see all

MaryDickinsonChamberlinMD

Dr. Chamberlin is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.